Vol 88, No 6 (2017)
Review paper
Published online: 2017-06-30

open access

Page views 2395
Article views/downloads 3207
Get Citation

Connect on Social Media

Connect on Social Media

The role of metalloproteinases in endometrial remodelling during menstrual cycle

Barbara Grzechocińska1, Filip Dąbrowski, Anna Cyganek, Grzegorz Panek, Mirosław Wielgoś
Pubmed: 28727135
Ginekol Pol 2017;88(6):337-342.

Abstract

Endometrium is the only tissue in the human body subject to cyclic transformations under the influence of ovarian steroid hormones. As estradiol and progesterone balance throughout the physiological menstrual cycle changes, so does the expression of metalloproteinases (MMPs). These endopeptides are responsible for keeping the balance between the process of synthesis and degradation of extracellular matrix proteins. Thus, MMP’s take part in sustaining physiological stability of the endometrium. A number of MMPs found in the endometrial tissue and their activity is related to menstrual cycle phase. This paper is an up-to-date review of literature of Medline database. The search was conducted for key words including “matrix metalloproteinases”, “MMPs”, “TIMPs” and “tissue inhibitors of metalloproteinases”. Over 1092 publications regarding interdependence and interplay between ovarian hormones and the role of various MMPs and their inhibitors in normal endometrial remodelling and in pathological conditions were analysed and critically reviewed.

References

  1. Goffin F, Munaut C, Frankenne F, et al. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium. Biol Reprod. 2003; 69(3): 976–984.
  2. Livingstone M, Fraser IS. Mechanisms of abnormal uterine bleeding. Hum Reprod Update. 2002; 8(1): 60–67.
  3. Noguchi Y, Sato T, Hirata M, et al. Identification and characterization of extracellular matrix metalloproteinase inducer in human endometrium during the menstrual cycle in vivo and in vitro. J Clin Endocrinol Metab. 2003; 88(12): 6063–6072.
  4. Snoek-van Beurden PAM, Von den Hoff JW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques. 2005; 38(1): 73–83.
  5. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med. 2008; 29(5): 290–308.
  6. Pretto CM, Gaide Chevronnay HP, Cornet PB, et al. Production of interleukin-1alpha by human endometrial stromal cells is triggered during menses and dysfunctional bleeding and is induced in culture by epithelial interleukin-1alpha released upon ovarian steroids withdrawal. J Clin Endocrinol Metab. 2008; 93(10): 4126–4134.
  7. Cornet PB, Galant C, Eeckhout Y, et al. Regulation of matrix metalloproteinase-9/gelatinase B expression and activation by ovarian steroids and LEFTY-A/endometrial bleeding-associated factor in the human endometrium. J Clin Endocrinol Metab. 2005; 90(2): 1001–1011.
  8. Davis GE, Pintar Allen KA, Salazar R, et al. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci. 2001; 114(Pt 5): 917–930.
  9. Wilkins-Port CE, Higgins SP, Higgins CE, et al. Complex Regulation of the Pericellular Proteolytic Microenvironment during Tumor Progression and Wound Repair: Functional Interactions between the Serine Protease and Matrix Metalloproteinase Cascades. Biochem Res Int. 2012; 2012: 454368.
  10. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92(8): 827–839.
  11. Stettner R, Bogusiewicz M, Rechberger T. [Matrix metalloproteinases and their inhibitors in ovarian cancer progression – diagnostic and therapeutic implications]. Ginekol Pol. 2009; 80(1): 47–53.
  12. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69(3): 562–573.
  13. Chegini N, Rhoton-Vlasak A, Williams RS. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding. Fertil Steril. 2003; 80(3): 564–570.
  14. Lockwood CJ. Mechanisms of normal and abnormal endometrial bleeding. Menopause. 2011; 18(4): 408–411.
  15. Slayden OvD, Brenner RM. A critical period of progesterone withdrawal precedes menstruation in macaques. Reprod Biol Endocrinol. 2006; 4(Suppl 1): S6.
  16. Brenner RM, Slayden OvD. Molecular and functional aspects of menstruation in the macaque. Rev Endocr Metab Disord. 2012; 13(4): 309–318.
  17. Henriet P, Cornet PB, Lemoine P, et al. Circulating ovarian steroids and endometrial matrix metalloproteinases (MMPs). Ann N Y Acad Sci. 2002; 955: 119–138.
  18. Wrzyszcz A, Wozniak M. On the origin of matrix metalloproteinase-2 and -9 in blood platelets. Platelets. 2012; 23(6): 467–474.
  19. Kokorine I, Marbaix E, Henriet P, et al. Focal cellular origin and regulation of interstitial collagenase (matrix metalloproteinase-1) are related to menstrual breakdown in the human endometrium. J Cell Sci. 1996; 109(Pt 8): 2151–2160.
  20. Freitas S, Meduri G, Le Nestour E, et al. Expression of metalloproteinases and their inhibitors in blood vessels in human endometrium. Biol Reprod. 1999; 61(4): 1070–1082.
  21. Critchley HOD, Robertson KA, Forster T, et al. Gene expression profiling of mid to late secretory phase endometrial biopsies from women with menstrual complaint. Am J Obstet Gynecol. 2006; 195(2): 406.e1–406.16.
  22. Dong JC, Dong H, Campana A, et al. Matrix metalloproteinases and their specific tissue inhibitors in menstruation. Reproduction. 2002; 123(5): 621–631.
  23. Chung HW, Lee JiY, Moon HS, et al. Matrix metalloproteinase-2, membranous type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium. Fertil Steril. 2002; 78(4): 787–795.
  24. Wingrove CS, Garr E, Godsland IF, et al. 17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta. 1998; 1406(2): 169–174.
  25. Fernandez-Patron C, Stewart KG, Zhang Y, et al. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res. 2000; 87(8): 670–676.
  26. Fullár A, Dudás J, Oláh L, et al. Remodeling of extracellular matrix by normal and tumor-associated fibroblasts promotes cervical cancer progression. BMC Cancer. 2015; 15: 256.
  27. Skinner JL, Riley SC, Gebbie AE, et al. Regulation of matrix metalloproteinase-9 in endometrium during the menstrual cycle and following administration of intrauterine levonorgestrel. Hum Reprod. 1999; 14(3): 793–799.
  28. O'Sullivan S, Medina C, Ledwidge M, et al. Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance – NO and MMP-9 interactions. Biochim Biophys Acta. 2014; 1843(3): 603–617.
  29. Rodgers WH, Matrisian LM, Giudice LC, et al. Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones. J Clin Invest. 1994; 94(3): 946–953.
  30. Gaide Chevronnay HP, Selvais C, Emonard H, et al. Regulation of matrix metalloproteinases activity studied in human endometrium as a paradigm of cyclic tissue breakdown and regeneration. Biochim Biophys Acta. 2012; 1824(1): 146–156.
  31. Matsuzaki S, Maleysson E, Darcha C. Analysis of matrix metalloproteinase-7 expression in eutopic and ectopic endometrium samples from patients with different forms of endometriosis. Hum Reprod. 2010; 25(3): 742–750.
  32. Isaka K, Nishi H, Nakai H, et al. Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer. 2003; 97(1): 79–89.
  33. Chernov AV, Sounni NE, Remacle AG, et al. Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. J Biol Chem. 2009; 284(19): 12727–12734.
  34. Jo YS, Lee GS, Nam SY, et al. Progesterone Inhibits Leptin-Induced Invasiveness of BeWo Cells. Int J Med Sci. 2015; 12(10): 773–779.
  35. Gaetje R, Holtrich U, Engels K, et al. Expression of membrane-type 5 matrix metalloproteinase in human endometrium and endometriosis. Gynecol Endocrinol. 2007; 23(10): 567–573.